Aripiprazole-associated rhabdomyolysis in a patient with schizophrenia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 23, Issue 3, 2011, Pages

  Chang, Kuo Yung ^a   Wu, Yung Fu ^a  

^a Beitou Armed Forces Hospital   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; MYOGLOBIN; QUETIAPINE;

ADULT; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; DISORIENTATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLUID THERAPY; FOLLOW UP; HUMAN; LETTER; LEUKOCYTE COUNT; MALE; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RHABDOMYOLYSIS; SCHIZOPHRENIA; SLURRED SPEECH; SOMNOLENCE; URINALYSIS;

EID: 80055015755     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/jnp.23.3.jnpe51     Document Type: Letter

References (4)

1. Luck RP, Verbin S: Rhabdomyolysis: a review of clinical presentation, etiology, diagnosis, and management. Pediatr Emerg Care 2008; 24:262-268
2. Marder SR, McQuade RD, Stock E, et al: Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61:123-136
3. Naber D, Lambert M: Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:1213-1219
4. Meltzer HY: Massive serum creatine kinase increases with atypical antipsy-chotic drugs: what is the mechanism and the message? Psychopharmacology (Berlin) 2000; 150:349-350